RCT | Intrathecal Tofersen did not improve clinical endpoints in patients with amyotrophic lateral sclerosis with mutations in SOD1.
27 Sep, 2022 | 13:09h | UTCTrial of Antisense Oligonucleotide Tofersen for SOD1 ALS – New England Journal of Medicine (link to abstract – $ for full-text)